First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions

Small-cell lung cancer (SCLC) is an aggressive and rapidly growing disease with poor prognosis. Despite intense efforts to improve clinical outcomes, platinum/etoposide chemotherapy has remained the most effective regimen for first-line extensive disease SCLC for decades. The addition of immune checkpoint inhibitors, and specifically programmed death-ligand 1 inhibitors, to standard platinum/etoposide, significantly improves survival and represents a promising advance in this field. However, identification of a predictive biomarker to refine patient selection is an area of unmet need. Further understanding of tumour immunity and mechanism of resistance is required to design novel strategies that improve survival. In this review, we describe recent developments and future directions on first-line immune checkpoint blockade for extensive disease-SCLC.

Automated summary

SCLC is an aggressive disease with poor prognosis, and platinum/etoposide chemotherapy remains the most effective regimen. The addition of immune checkpoint inhibitors has shown promising results in improving survival, but further research is needed to identify predictive biomarkers for patient selection.